JAK2 and chronic thromboembolic pulmonary hypertension: The involvement of the JAK/STAT cascade in inflammation and fibrosis in lung tissue has driven studies on the use of the JAK1 and JAK2 inhibitor ruxolitinib in chronic thromboembolic pulmonary hypertension [101].